All In Biotech

Drug Trial Radar · NCT00703326

Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer

Last checked: Nov 20, 2026Latest source record: Dec 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,144 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,144

Actual

Start

Aug 6, 2008

Primary completion

Mar 31, 2013

Study completion Nov 19, 2020

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Jun 23, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to compare the progression-free survival (PFS) of the drug combination ramucirumab plus docetaxel to placebo plus docetaxel in previously untreated participants with human epidermal growth factor receptor 2 (HER2)-negative, unresectable, locally-recurrent or metastatic breast cancer.

Conditions

  • Breast Cancer

Interventions

  • ramucirumab (IMC-1121B)Biological

    Ramucirumab (IMC-1121B) is administered at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.

  • docetaxelDrug

    Docetaxel is administered at a dose of 75 milligrams per square meter (mg/m²) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.

  • PlaceboOther

    Placebo comparator for ramucirumab (IMC-1121B) administered at a dose of 10 mg/kg as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Randomization to disease progression or death or until data cutoff of 31 Mar 2013 (up to 56 months)

Locations

232 sites in 23 countries. Site status is shown where the registry gives one.

  • ImClone Investigational Site

    Birmingham, Alabama

  • ImClone Investigational Site

    Mobile, Alabama

  • ImClone Investigational Site

    Chandler, Arizona

  • ImClone Investigational Site

    Gilbert, Arizona

  • ImClone Investigational Site

    Mesa, Arizona

  • ImClone Investigational Site

    Alhambra, California

  • ImClone Investigational Site

    Bakersfield, California

  • ImClone Investigational Site

    Chula Vista, California

  • ImClone Investigational Site

    La Mesa, California

  • ImClone Investigational Site

    Los Angeles, California

  • ImClone Investigational Site

    Oceanside, California

  • ImClone Investigational Site

    Pasadena, California

  • ImClone Investigational Site

    Pasadena, California

  • ImClone Investigational Site

    San Diego, California

  • ImClone Investigational Site

    Santa Barbara, California

  • ImClone Investigational Site

    Santa Maria, California

  • ImClone Investigational Site

    Santa Monica, California

  • ImClone Investigational Site

    Solvang, California

  • ImClone Investigational Site

    Valencia, California

  • ImClone Investigational Site

    Aurora, Colorado

  • ImClone Investigational Site

    Fort Lauderdale, Florida

  • ImClone Investigational Site

    Gainesville, Florida

  • ImClone Investigational Site

    New Port Richey, Florida

  • ImClone Investigational Site

    Atlanta, Georgia

  • ImClone Investigational Site

    Atlanta, Georgia

  • ImClone Investigational Site

    Macon, Georgia

  • ImClone Investigational Site

    Marietta, Georgia

  • ImClone Investigational Site

    Alton, Illinois

  • ImClone Investigational Site

    Chicago, Illinois

  • ImClone Investigational Site

    Chicago, Illinois

  • ImClone Investigational Site

    Skokie, Illinois

  • ImClone Investigational Site

    Elkhart, Indiana

  • ImClone Investigational Site

    Mishawaka, Indiana

  • ImClone Investigational Site

    South Bend, Indiana

  • ImClone Investigational Site

    Westville, Indiana

  • ImClone Investigational Site

    Lexington, Kentucky

  • ImClone Investigational Site

    Lansing, Michigan

  • ImClone Investigational Site

    Saint Joseph, Michigan

  • ImClone Investigational Site

    Minneapolis, Minnesota

  • ImClone Investigational Site

    Southaven, Mississippi

Showing 40 of 232 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.